The Effect of Natrox® Oxygen Wound Therapy on the Healing Rate of Chronic Diabetic Foot Ulcers

NCT ID: NCT03905863

Last Updated: 2021-11-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 145 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-06-04
• Study Completion Date: 2020-10-18

Brief Summary

A Multicentre Randomized Controlled Trial to Investigate the Effect of Natrox Topical Oxygen Wound Therapy on the Healing rates of Diabetic Foot Ulcers.

Detailed Description

Patients with diabetic foot ulcers will be enrolled into the trial at multiple wound care centers and hospital research centers across the United States of America. After qualifying per protocol, patients will be randomized to receive standard wound care or standard wound care plus Topical Oxygen Wound Therapy for their wounds. Patients will be monitored for 12 weeks. The primary comparator between the groups will be complete wound healing at 12 weeks, but other parameters will be assessed, such as pain, wound size reduction and infection status.

Conditions

Diabetic Foot Ulcer; Surgical Wound

Keywords

topical oxygen; topical oxygen treatment; diabetic foot ulcer; non-healing wound; surgical site; pain; wound size; healing; infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Standard of care arm

SOC was defined to include wound cleansing with sterile water or saline solution, and gentle irrigation of the study ulcer with warm tap water; sharp debridement using a standardised protocol based on TIME principles for wound bed preparation; offloading with a TCC twice in the first week and weekly thereafter (all exceptions had to be agreed by the lead investigator; a fixed ankle walker boot or similar device was acceptable as an alternative, but shoe inserts were not deemed to provide sufficient offloading); moisture balance was provided using a hydrofibre or alginate dressing. In addition, patients were instructed on adherence to the protocol and given instructions to call their clinic if they suspected any signs of an infection.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Intervention arm

Same protocol as SOC only but were also provided with a Natrox® Oxygen Wound Therapy System, consisting of two elements: the Natrox® OG and the Natrox® ODS. The OG is a multi-use battery powered device which generates oxygen though water electrolysis at a rate of 15mL/hr. The ODS is a sterile, single use device that allows wound exudate to pass through to the secondary dressing while allowing the diffusion of oxygen across the wound bed. It connects directly to the OG via a thin flexible fine-bore tube. While the ODS can remain in situ for 7 days, it should be changed at each dressing change, based on exudate level or clinical judgement. This is a battery-operated system with a 30-hour battery life; the kit includes two interchangeable, rechargeable batteries. Each participant was advised to charge one battery while the other was in use, as the battery required changing daily. The oxygen generator is worn in a holster so that patients can remain ambulatory.

Group Type: ACTIVE_COMPARATOR

Natrox® Oxygen Wound Therapy

Intervention Type: DEVICE

A battery-operated device which delivers pure humidified oxygen to the wound bed through water electrolysis via a sterile oxygen delivery system.

Interventions

Natrox® Oxygen Wound Therapy

A battery-operated device which delivers pure humidified oxygen to the wound bed through water electrolysis via a sterile oxygen delivery system.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Subjects are male or female, 18 years of age or older. At least 50% of the enrolled population must be ≥ 65 years of age.

2. Subjects with one of the following wounds:

A. Diabetic foot ulcer present for greater than 4 weeks (documented in the medical record) but less than 12 months duration if being treated with active SOC.

B. Minor amputation wound sites

3. Subject has clinical documentation of no visible wound improvement in the after 4 weeks of standard of care. Objectively, less than 40% healing in the past four weeks from the first treatment visit.

4. Study ulcer is a minimum of 0.5 cm2 and a maximum of 25 cm2 at first treatment visit

5. Subjects' wound score on ISDA tool is Grade 1 or 2.

6. The subject is able and willing to follow the protocol requirements

7. Subject has signed informed consent

8. Adequate circulation to the affected foot as demonstrated by a dorsum transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg; an ABI between 0.7 and ≤ 1.3, or TBI of >6 within 3 months of the first Screening Visit.

9. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence).

10. The target ulcer has been offloaded for at least 14 days prior to randomization.

Exclusion Criteria

1. Subject has a known life expectancy of < 1 year

2. Subject or caregiver is unable to manage the Natrox® device (charge and change batteries daily)

3. Subject has ulcers that are completely necrotic or if the clinician feels it is clinically necessary to cover the wound surface in gel or creams that would prevent the transmission of oxygen to the wound surface.

4. Subject has major uncontrolled medical disorders such as serious cardiovascular, renal, liver or pulmonary disease, lupus, palliative care or sickle cell anemia.

5. Subject currently being treated for an active malignant disease or subjects with history of malignancy within the wound.

6. The Subject has other concurrent conditions that in the opinion of the Investigator may compromise subject safety

7. Known contraindications for the Natrox system

8. Known allergies to any of the Natrox system components

9. Concurrent participation in another clinical trial that involves an investigational drug or device that would interfere with this study.

10. Index ulcer has reduced in area by 20% or more after 2 weeks of standard of care from the first screening visit (S1) to the TV1/randomization visit.

11. Subject is pregnant or breast feeding.

12. Subjects with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to first Screening Visit, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.

13. Index ulcer has been previously treated with tissue engineered materials (e.g. Apligraf® or Dermagraft®) or other scaffold materials (e.g. Oasis, Matristem) within the last 30 days preceding the first treatment visit.

14. Affected extremity requiring hyperbaric oxygen during the trial or within 2 weeks of treatment visit 1.

15. Known HbA1C >12%

16. An ulcer that has visible signs of improvement in the four weeks prior to randomization defined objectively as a 40% reduction in surface area in the four weeks prior to enrollment.

17. An ulcer that has healed by more than 20% in the 2 weeks prior to screening: "historical" run-in period.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

SerenaGroup, Inc.

NETWORK

Sponsor Role: collaborator

Inotec AMD Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Thomas Serena

Role: STUDY_DIRECTOR

SerenaGroup, Inc.

Locations

New Hope Podiatry Clinic

Los Angeles, California, United States

MedCare Research

Miami, Florida, United States

San Marcus Research Clinic

Miami Lakes, Florida, United States

Global Health Research Center Inc

Miami Lakes, Florida, United States

Barry University Clinical Research

North Miami Beach, Florida, United States

Royal Research Corp

Pembroke Pines, Florida, United States

Doctors Research Network

South Miami, Florida, United States

Pharma Research Associates

Westchester, Florida, United States

Wahab Consulting and Research

Las Vegas, Nevada, United States

Cleveland Foot and Ankle Clinic

Cleveland, Ohio, United States

Tulsa Bone and Joint

Tulsa, Oklahoma, United States

The Foot and Ankle Wellness Center of Western Pennsylvania

Ford City, Pennsylvania, United States

Antria

Indiana, Pennsylvania, United States

ACMH Snyder Institute

Kittanning, Pennsylvania, United States

SerenaGroup Research Institute

Pittsburgh, Pennsylvania, United States

El Campo Memorial Hospital

El Campo, Texas, United States

Allure Health LLC

Friendswood, Texas, United States

Pinnacle Foot and Ankle Center

Houston, Texas, United States

Mercury Clinical Research

Webster, Texas, United States

Clinical Research Management Group

Coto Laurel, Ponce, Puerto Rico

Countries

United States; Puerto Rico

Provided Documents

Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form

View Document

Other Identifiers

1

Identifier Type: -

Identifier Source: org_study_id